MedTrace Logo

A Novel Iron-Based Supplement for Athletes Aged 18-25: Phase II

NCT06269913 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-30

No results posted yet for this study

Summary

Female endurance athletes are susceptible to iron deficiency and this can impact their exercise performance. This study aims to assess the efficacy of a novel iron supplement in improving iron status, gut microbiome, and exercise performance in endurance-trained females.

Conditions

  • Iron Deficiencies

Interventions

OTHER

FeSC

Iron/yeast complex

Sponsors & Collaborators

  • Mitacs

    collaborator INDUSTRY

  • Natural Sciences and Engineering Research Council, Canada

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Jane Shearer, PhD · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-17
Primary Completion
2025-03-12
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06269913 on ClinicalTrials.gov